1904P - Factors and trends associated with alcohol intake in patients with breast cancer

Background

Alcohol intake (AI) increases the risk of breast cancer (BC) and may impair cancer prognosis. Many US cancer survivors self-report regular AI, including some who display excessive drinking behaviors. As AI is a potentially modifiable risk factor for cancer-specific outcomes, a better understanding of factors associated with AI in BC survivors could elucidate who is most in need of targeted education to support reductions in AI during survivorship. This study aimed to describe AI prevalence soon after BC diagnosis and changes over the first year of BC survivorship in a large longitudinal cohort study of patients diagnosed with BC.

Methods

Adult patients newly diagnosed (within 1 year) with BC seen at Mayo Clinic Rochester between 2013-2023 (N=3247) were invited to enroll in the Mayo Clinic Breast Disease Registry. Consenting participants completed self-reported questionnaires at both baseline and one year after diagnosis (N=2259), including questions about weekly or daily AI and other demographic factors. This longitudinal cohort study was approved by the institutional review board.

Results

Among 2259 participants who reported their weekly AI (mean age 58.4 years, 99.3% female, 95.4% white, 93.6% stage 0-3 BC, 4.5% stage 4 BC), 189 (8.4%) reported AI of >10 drinks weekly on the baseline survey. There was a decrease in AI over the year of follow-up (p<0.001): the percentage of patients reporting no AI increased from 28.3% at baseline to 61.1% at year 1. Of the 316 who reported drinking 5-9 drinks and the 120 who reported 10-14 drinks per week at baseline, 173 (54.7%) and 51 (42.5%), respectively, reduced to 1-4 drinks per week at year 1. In univariate models, Asian race, grade school education, and not having a bilateral mastectomy were associated with no AI at baseline. Lack of AI at year 1 was associated with less financial stability, locally advanced (T3 and T4, N3) or metastatic (M1) disease, and receipt of chemotherapy (p<0.05).

Conclusions

Many people who self-reported AI soon after a breast cancer diagnosis stopped drinking by 1 year after diagnosis. However, 9.1% of women still consumed >5 drinks per week at one year after their diagnosis. Future studies to understand factors influencing AI in BC survivors are critical to inform and target alcohol-reduction interventions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Mayo Clinic.

Funding

NIH P30CA015083.

Disclosure

F.J. Couch: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Research Funding: GRAIL. C.C.M. O'Sullivan: Financial Interests, Institutional, Research Funding: Lilly, Pfizer, Eisai, Bavarian Nordic, Minnemarita Therapeutics, nFerence, AstraZeneca, Biovica; Financial Interests, Personal, Financially compensated role, Honoraria: OncLive, Medscape, AstraZeneca, Pfizer. All other authors have declared no conflicts of interest.